Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC

This article was originally published in The Pink Sheet Daily

Executive Summary

Enrollment in a Phase III trial in NSCLC patients is suspended after early mortality rates were seen in the treatment arm.

You may also be interested in...



Amgen/Takeda To Re-start Motesanib Lung Cancer Trial

Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee

Amgen/Takeda To Re-start Motesanib Lung Cancer Trial

Amgen and partner Takeda are getting set to re-start a Phase III trial of the vascular endothelial growth factor inhibitor motesanib in non-small cell lung cancer, after a conditional go-ahead from an independent data monitoring committee

Motesanib Gets Green Light In Lung Cancer Trial

Amgen/Takeda now altering Phase III design for a smaller patient pool.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067042

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel